Ainnocence is a next-generation biotech company aiming to create a self-evolving modularized intelli
Location: United States, California, Sacramento
Employees: 11-50
Total raised: $4.6M
Founded date: 2021
Investors 1
| Date | Name | Website |
| 20.12.2022 | Iaso Ventu... | iasoventur... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.06.2021 | Seed | $4.6M | Genesis Ca... |
Mentions in press and media 22
| Date | Title | Description |
| 30.03.2026 | Ainnocence's CarbonAI®, a Proprietary AI Engine for De Novo Small-Molecule and PROTAC Design and Optimization | Platform screens up to 10 billion compounds in hours, delivering wet-lab-ready candidates in weeks without requiring 3D protein structures CarbonAI® was designed from the ground to solve that problem. By working directly from sequence, we e... |
| 25.03.2026 | SentinusAI® Goes Live: Ainnocence’s AI Platform Turns Sequence Data Into Discovery Decisions in Days | The AI platform for therapeutic antibody and biologics discovery is now open for subscription. SAN FRANCISCO , CA, UNITED STATES, March 25, 2026 /EINPresswire.com/ -- The Challenge Therapeutic antibody development still depends heavily on s... |
| 06.03.2026 | Ainnocence Calls for Collaboration to Deploy AI-Driven Antibody Discovery Against World’s Deadliest Infectious Diseases | AI designed, mutation resistant broad neutralizing antibodies against multiple SARS-CoV-2 strains A Study shows mutation-resistant antibodies with 269×affinity, a proof point for CEPI’s 100 Days Mission and closing the therapeutic gap for 2... |
| 14.01.2026 | How sequence-based AI achieve whole genome screening for billions of small molecule and antibody candidates in hours | Featured in C&EN: Discover how sequence-based AI is transforming drug discovery, accelerating and broadening the search for new therapeutics Destructed Drug Discovery: Sequence-Based AI for Rapid Evaluation of Small Molecules and Antibo... |
| 13.01.2026 | Ainnocence and Phase Advance Enter Industry-First AI Collab to Reduce Drug Development Timeline and Clinical Trial Risk | Phase Advance Logo Ainnocence Logo Dr. Tawanda Gumbo, Phase Advance CEO And Dr. Lurong Pan, Ainnocence CEO The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development process for i... |
| 09.01.2026 | NatmolAI™: Computational Expansion and Optimization of Natural-Product Chemical Space | NatmolAI™, Natural Molecule AI Engine Our goal with NatmolAI™ is not to replace natural products, but to understand and extend them” — Dr. Lurong Pan, CEO of Ainnocence SAN FRANCISCO , CA, UNITED STATES, January 8, 2026 /EINPresswire.com/ -... |
| 01.01.2026 | Beauty Engineered: Ainnocence Launches CosmeticAI™ to Accelerate AI-Driven Innovation in Skincare and Beauty Products | Our goal with CosmeticAI™ was to make cosmetic ingredient development predictable rather than exploratory” — Dr. Lurong Pan, CEO of Ainnocence SAN FRANSICO, CA, UNITED STATES, January 1, 2026 /EINPresswire.com/ -- Ainnocence, a next-generat... |
| 19.12.2025 | AI Meets the Formula: Predictive Intelligence Redefines Chemical Design and Manufacturing | Ainnocence’s FormulaAI™ platform for sequence-based chemical formulation intelligence, enabling in silico performance prediction, process optimization and scale-up assessment. FormulaAI™, an AI-based platform that brings predictive modeling... |
| 23.10.2025 | Antibody Design at Lightning Speed: AI-Driven Precision for Complex Targets | Ainnocence’s next-generation AI platform revolutionizes biologics discovery, achieving unprecedented scale, precision and speed in antibody and protein design. Our AI platform brings protein and antibody design into a new era” — Dr. Lurong ... |
| 25.09.2025 | Redefining Chemistry: How AI Shrinks Small-Molecule Discovery from Years to Weeks | Ainnocence’s CarbonAI® Platform for AI-Powered Small Molecule Drug Design — Enabling De Novo Generation, Lead Optimization, and Off-Target Prediction Without Structural Data Chemistry shouldn’t take years to show you what’s possible” — Dr. ... |
Show more